fda

Ignite It
4 min read • February 12, 2024

‘FDA Grants Priority Review Of MDMA-Assisted Therapy For PTSD, Psychedelics Drug Development Company Says’ – Marijuana Moment

Ignite It
5 min read • January 22, 2024

Rescheduling Cannabis: 4 Potential Effects Of A Shift To Schedule III

Ignite It
3 min read • January 4, 2024

Hemp Should Be Deemed Compliant Unless It Exceeds 1% Total THC, 1 Of 7 Objectives For New Farm Bill

Ignite It
3 min read • January 2, 2024

Biden Considers Marijuana Rescheduling: Boon Or Bust For The Industry? Former Top FDA Official Weighs In

Ignite It
4 min read • April 12, 2023

EXCLUSIVE: Descheduling/Rescheduling Cannabis: Will It Be An Expeditious Path To 280E Relief? ‘This Is The One Moment To Do It’

Ignite It
3 min read • March 30, 2023

FDA’s Scarce CBD Regulations, MO Weed Measures, Cannabis In NJ, Kratom’s Legal Statues & More

Ignite It
2 min read • February 27, 2023

SciSparc Signs Agreement For The Supply Of CBD-Rich Cannabis Oil For Its Clinical Trial On Children With Autism Spectrum Disorder

Ignite It
2 min read • February 15, 2023

Medical Cannabis For Autism: Zelira Receives $8.6M For FDA Clinical Trials For Treatment

Ignite It
3 min read • January 26, 2023

FDA Says No To CBD Marketing As Food Or Dietary Supplement, Expert Warns Decision Could Effect Cannabis Legislation

Ignite It
1 min read • January 26, 2023

FDA Denying 3 Citizen Petitions That Asked Agency To Conduct Rulemaking To Allow Marketing Of CBD Products As Dietary Supplements

Ignite It
1 min read • January 26, 2023

FDA Concluded New Regulatory Pathway For CBD Is Needed That Balances Individuals’ Desire For Access To CBD Products; FDA Convened High-Level Internal Working Group To Explore Potential Regulatory Pathways For CBD Products

Ignite It
4 min read • January 23, 2023

FDA Issues Final Clinical Research Guidance For Cannabis, Here Are The Agency’s Recommendations

Browse By Channels

 After-Hours Center
 Analyst Color
 Analyst Ratings
 Andy Barr
 Asia
 Asset Sales
 Be Your Own Boss
 Binary Options
 Biotech
 Bonds
 Broad U.S. Equity ETFs
 Buybacks
 california cannabis
 Cannabis
 cannabis earnings
 cannabis farms
 cannabis study
 Christopher Dillis
 CNBC
 Commodities
 Congress cannabis
 Congress hemp
 Contracts
 Crowdsourcing
 Cryptocurrency
 Currency ETFs
 Dividends
 Downgrades
 Earnings
 Earnings Beats
 Earnings Misses
 Econ #s
 Economics
 Education
 Emerging Market ETFs
 Emerging Markets
 Entertainment
 Entrepreneurship
 Equities
 ESG
 ETFs
 Eurozone
 Events
 Exclusives
 Fast Money
 FDA
 Federal Reserve
 Financial Advisors
 Financing
 Fintech
 first quarter earnings
 Forex
 Futures
 Gaming
 General
 Global
 Government
 Guidance
 Health Care
 Hedge Funds
 hemp bill
 hemp legalization
 hemp regulation
 Hot
 illegal cannabis farms
 Initiation
 Insider Trades
 Insurance
 Interview
 intoxicating hemp-derived products
 Intraday Update
 IPOs
 James Comer
 Large Cap
 Latin America
 Legal
 Long Ideas
 M&A
 Macro Economic Events
 Macro Notification
 Management
 marijuana
 Market Summary
 Market-Moving Exclusives
 Markets
 Media
 Mid Cap
 Movers
 Movers & Shakers
 New ETFs
 News
 Offerings
 Opinion
 Options
 Penny Stocks
 Personal Finance
 Politics
 Pre-Market Outlook
 Press Releases
 Previews
 Price Target
 Psychedelics
 Psychology
 Real Estate
 Regulations
 REIT
 Reiteration
 Rescheduling
 Restaurants
 Retail Sales
 Reviews
 Rumors
 SEC
 Sector ETFs
 Short Ideas
 Short Sellers
 Signals
 Small Business
 Small Cap
 Small Cap Analysis
 Social Media
 Specialty ETFs
 Sports
 Sports Betting
 Startups
 Stock Split
 Success Stories
 Taxes
 Tech
 Technicals
 THC
 Top Stories
 Topics
 Trading Ideas
 Travel
 UC Berkeley Cannabis Research Center
 unlicensed cannabis
 Upgrades
 WIIM

Join the Cannabis Revolution

Ready to access the most aggressive cannabis intelligence platform? Get started with IGNITE IT today.